NEW YORK (GenomeWeb) – Guardant Health said yesterday that it has signed an exclusive distribution and marketing partnership with Teva Pharmaceuticals subsidiary Oncotest-Teva to make Guardant Health's Guardant360 available to patients with advanced cancer in Israel.

One of the first commercially available laboratory-developed liquid biopsy tests in the US, Guardant360 detects and analyzes DNA fragments shed from solid tumors into the blood of patients with advanced cancers, including all four major classes of somatic genomic alterations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.